Brain injection trial aims to slow Alzheimer's by targeting toxic protein
NCT ID NCT06372821
Summary
This early-stage study is testing whether a new drug called NIO752 can reduce the brain's production of tau protein, which forms toxic tangles in Alzheimer's disease. Researchers will give the drug via spinal injection to 10 participants with mild to moderate Alzheimer's and measure tau levels in their spinal fluid. The main goal is to see if the drug safely lowers tau production, which could potentially slow disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University College London Hospitals NHS Foundation Trust
RECRUITINGLondon, NW1 2PG, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University in St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.